StockNews.com Initiates Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI)

StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research note released on Wednesday. The brokerage issued a hold rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Price Performance

BCLI opened at $1.40 on Wednesday. The firm’s fifty day moving average price is $1.74 and its two-hundred day moving average price is $2.05. The company has a market capitalization of $7.98 million, a price-to-earnings ratio of -0.29 and a beta of 0.74. Brainstorm Cell Therapeutics has a 1 year low of $1.05 and a 1 year high of $11.25.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.